Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report

被引:39
作者
Uzun, Oe [1 ]
机构
[1] Gulhane Mil Med Acad, Dept Psychiat, TR-06018 Ankara, Turkey
关键词
glutamatergic agent; lamotrigine; obsessive-compulsive disorder; treatment-resistant; SEROTONIN; STRATEGIES; SCALE; OCD;
D O I
10.1177/0269881108098809
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Obsessive-compulsive disorder (OCD) is a relatively common, often chronic and disabling disorder with high rates of partial and/or absent response to standard, recommended treatments. We report a case of treatment-resistant OCD that was successfully treated with a pharmacological augmentation of lamotrigine plus clomipramine. The patient, a 59-year-old woman, was on a stable dose of clomipramine (225 mg/day) when she was started on lamotrigine (up to 150 mg/day). After 10 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the Yale-Brown Obsessive-Compulsive Scale. This case suggests some preliminary evidence that the addition of glutamatergic agent lamotrigine may be useful in treatment-resistant OCD. However, further controlled studies are needed to support this finding.
引用
收藏
页码:425 / 427
页数:3
相关论文
共 50 条
[31]   Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study [J].
Hollander, E ;
Rossi, NB ;
Sood, E ;
Pallanti, S .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04) :397-401
[32]   Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms [J].
Poyurovsky, M. ;
Glick, I. ;
Koran, L. M. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (06) :861-866
[33]   Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder [J].
Seo, Eun Hyun ;
Kim, Seung-Gon ;
Lee, Jae-Hon ;
Yoon, Hyung-Jun .
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2023, 21 (03) :604-608
[34]   Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder:: an open trial [J].
Metin, Ö ;
Yazici, K ;
Tot, S ;
Yazici, AE .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2003, 18 (06) :463-467
[35]   Double-Blind Study of Dextroamphetamine Versus Caffeine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder [J].
Koran, Lorrin M. ;
Aboujaoude, Elias ;
Gamel, Nona N. .
JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (11) :1530-1535
[36]   Ondansetron Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder: A Randomized Placebo-Controlled Clinical Trial [J].
Sepehrmanesh, Zahra ;
Adel, Mehdi ;
Ahmadvand, Afshin ;
Sehat, Mojtaba .
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2020, 22 (05)
[37]   Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder A Preliminary, Single-Blind, Prospective Study [J].
Pallanti, Stefano ;
Bernardi, Silvia ;
Antonini, Sarah ;
Singh, Nikhilesh ;
Hollander, Eric .
CNS DRUGS, 2009, 23 (12) :1047-1055
[38]   Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder [J].
Bejerot, S ;
Bodlund, O .
ACTA PSYCHIATRICA SCANDINAVICA, 1998, 98 (05) :423-424
[39]   Augmentation strategies in obsessive-compulsive disorder [J].
Arumugham, Shyam Sundar ;
Reddy, Janardhan Y. C. .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (02) :187-203
[40]   Antipsychotic augmentation in the treatment of obsessive-compulsive disorder [J].
Thamby, Abel ;
Jaisoorya, T. S. .
INDIAN JOURNAL OF PSYCHIATRY, 2019, 61 (07) :S51-S57